| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
|
Gynecol Oncol
|
2005
|
1.91
|
|
2
|
Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature.
|
Anticancer Res
|
2005
|
1.06
|
|
3
|
Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
|
Int J Oncol
|
2009
|
1.05
|
|
4
|
Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.
|
BMC Cancer
|
2013
|
1.04
|
|
5
|
Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study.
|
Cancer Invest
|
2005
|
1.00
|
|
6
|
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.
|
BMC Med
|
2010
|
1.00
|
|
7
|
Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
|
Oncology
|
2009
|
0.97
|
|
8
|
Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study.
|
Oncology
|
2006
|
0.95
|
|
9
|
Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
|
Clin Breast Cancer
|
2012
|
0.91
|
|
10
|
Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group.
|
J Thorac Oncol
|
2007
|
0.91
|
|
11
|
Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
|
Crit Rev Oncol Hematol
|
2008
|
0.90
|
|
12
|
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
|
J Transl Med
|
2012
|
0.89
|
|
13
|
Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines.
|
Int J Oncol
|
2009
|
0.88
|
|
14
|
MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.
|
J Oncol
|
2009
|
0.87
|
|
15
|
A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer.
|
Int J Gastrointest Cancer
|
2005
|
0.85
|
|
16
|
Thymidylate synthase inhibition induces p53-dependent and p53-independent apoptotic responses in human urinary bladder cancer cells.
|
J Cancer Res Clin Oncol
|
2010
|
0.84
|
|
17
|
A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients.
|
Cancer Chemother Pharmacol
|
2015
|
0.84
|
|
18
|
Caspase 8 and caspase 9 gene polymorphisms and susceptibility to gastric cancer.
|
Gastric Cancer
|
2011
|
0.83
|
|
19
|
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study.
|
Anticancer Res
|
2005
|
0.83
|
|
20
|
Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study.
|
Eur Urol
|
2004
|
0.81
|
|
21
|
Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
|
Oncology
|
2008
|
0.81
|
|
22
|
A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.
|
BMC Med
|
2011
|
0.81
|
|
23
|
Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.
|
PLoS One
|
2013
|
0.80
|
|
24
|
Effects of stromal cell-derived factor-1 and survivin gene polymorphisms on gastric cancer risk.
|
Mol Med Rep
|
2012
|
0.80
|
|
25
|
Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
|
Gynecol Oncol
|
2007
|
0.80
|
|
26
|
The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
|
Urology
|
2005
|
0.78
|
|
27
|
Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study.
|
Oncol Rep
|
2011
|
0.78
|
|
28
|
Comparison of HER2 detection methods between central and regional laboratories in Greece.
|
Clin Breast Cancer
|
2007
|
0.78
|
|
29
|
Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
|
Cancer Invest
|
2008
|
0.77
|
|
30
|
Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial.
|
Anticancer Res
|
2003
|
0.76
|
|
31
|
Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) phase II study.
|
Med Oncol
|
2007
|
0.76
|
|
32
|
Irinotecan and oxaliplatin combination, as second-line treatment, in fluoropyrimidine-pretreated advanced colorectal cancer. A phase II study by the Hellenic Cooperative Oncology Group (HeCOG).
|
Tumori
|
2005
|
0.76
|
|
33
|
Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
|
Anticancer Drugs
|
2004
|
0.75
|
|
34
|
PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.
|
Cancer Chemother Pharmacol
|
2015
|
0.75
|
|
35
|
A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
|
Am J Clin Oncol
|
2002
|
0.75
|
|
36
|
Aims, design and methods of a case-control study for the assessment of the role of dietary habits, eating behaviors and environmental factors, on the development of breast cancer.
|
Maturitas
|
2012
|
0.75
|
|
37
|
Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
|
Anticancer Res
|
2010
|
0.75
|
|
38
|
E-Selectin S128R gene polymorphism in gastric cancer.
|
Int J Biol Markers
|
2013
|
0.75
|
|
39
|
Prediction of response to combination chemotherapy with irinotecan in Greek patients with metastatic colorectal cancer.
|
J Cancer Res Ther
|
2016
|
0.75
|